The Role Of Pentoxifylline And Iloprost In Prevention Of Ischemia-reperfusion injury in Experimental Model Of Intestine Ischemia-reperfusion In Rats

Intestinal ischemia-reperfusion (I/R) injury can lead to multiple organ failure and death. The aim of this study was to investigate the effects of pentoxifylline and iloprost administered before reperfusion in intestinal ischemia. In total, 25 male Wistar Albino rats weighing 250-300 g were divided...

Full description

Saved in:
Bibliographic Details
Published inUlusal travma ve acil cerrahi dergisi = Turkish journal of trauma & emergency surgery : TJTES Vol. 24; no. 5; p. 398
Main Author Abakay, Ugur
Format Journal Article
LanguageEnglish
Published Turkey 01.09.2018
Online AccessGet full text

Cover

Loading…
More Information
Summary:Intestinal ischemia-reperfusion (I/R) injury can lead to multiple organ failure and death. The aim of this study was to investigate the effects of pentoxifylline and iloprost administered before reperfusion in intestinal ischemia. In total, 25 male Wistar Albino rats weighing 250-300 g were divided into five groups each comprising five subjects: control group (n=5), sham group (n=5, no I/R), I/R group (n=5, 45 min ischemia, and 120 min reperfusion), I/R + pentoxifylline group (n=5, 45 min ischemia following intraperitoneal 50 mg/kg pentoxifylline and 120 min reperfusion), and I/R + iloprast group (n=5, 45 min ischemia followed by intraperitoneal 2 mcg /kg iloprost and 120 min reperfusion). At the end of the experiment, ileum specimens were stained using hematoxylin-eosin and histopathologically evaluated using the Chiu score. Isometric contraction-relaxation responses were recorded using organ baths for contraction-relaxation responses. Pentoxifylline provided a significant improvement in response to histopathological and contraction-relaxation responses. Although iloprost provided recovery in reperfusion injury, it was not statistically significant. Our findings demonstrate that pentoxifylline may be promising in preventing small bowel ischemia-reperfusion injury. We concluded that further clinical and experimental studies for iloprost are needed.
ISSN:1306-696X
DOI:10.5505/tjtes.2018.22227